Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 17/20 | 0.65 |
| ▸ | PPARG | P37231 | 16/20 | 0.65 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4012672 | 0.93 | PPARA (0.65) | PPARAPPARG | |
| SCHEMBL4013379 | 0.92 | PPARA (0.55) | PPARAPPARGPPARDNR1H2NR1H3 | |
| SCHEMBL4012839 | 0.92 | PPARA (0.66) | PPARAPPARGPPARDNR1H2NR1H3 | |
| SCHEMBL4013902 | 0.92 | PPARA (0.66) | PPARAPPARGPPARDNR1H2NR1H3 | |
| SCHEMBL4017608 | 0.90 | PPARA (0.55) | PPARAPPARGPPARDNR1H2NR1H3 | |
| SCHEMBL6206380 | 0.81 | PPARA (0.42) | PPARAPPARG | |
| SCHEMBL4013188 | 0.80 | PPARG (0.49) | PPARAPPARGPPARD | |
| SCHEMBL4014719 | 0.80 | PPARA (0.70) | PPARAPPARGNR1H2NR1H3 | |
| SCHEMBL13924221 | 0.78 | PPARA (0.85) | PPARAPPARG | |
| SCHEMBL4014778 | 0.78 | PPARA (0.85) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091230-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | claimed |
| EP-1366012-A4 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | MERCK & CO INC (US) | 2005-11-02 | — | — | EP | claimed |
| US-20040092596-A1 | 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2004-05-13 | — | — | US | claimed |
| EP-1366012-A2 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2003-12-03 | — | — | EP | claimed |
| WO-2002064094-A2 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | claimed |
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7091230-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060122242-A1 | 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2006-06-08 | — | — | US | disclosed |
| US-20040092596-A1 | 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122242-A1 | 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
| US-20040092596-A1 | 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.